Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth

• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Latest patent issuance furthers the Company’s Global IP strategy
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions

July 23, 2020, (Syracuse, New York) - private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the Australian Government has issued Patent No. 2015267006 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using the Company’s small molecule, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

“This latest patent issuance lays the platform for our impending commercialization strategy to bring products like ZetaMet™ (Zeta-BC-003) to all continents with patients suffering from cancerous metastatic lesions,” said Joe C. Loy, CEO of Zetgen Therapeutics, Inc.

This patent follows the previously issued U.S. Patent No. 102656437 covering the use of methods to promote controlled bone creation and destruction as a means to heal large bone segmental defects and U.S. Patent No. 10208306 and South African PCT. 201700029 covering the use of a method for stimulating bone growth using a small molecule. The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions.